Core Points - I-Mab, a U.S.-based global biotech company, focuses on developing precision immuno-oncology agents for cancer treatment [2] - The management team of I-Mab will participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference, scheduled for February 11-12, 2025 [1] - The conference will include a company presentation and one-on-one meetings, with I-Mab's presentation set for February 11, 2025, from 4:00 to 4:30 PM ET [1] Company Overview - I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey [2] - The company is dedicated to advancing innovative therapies in the field of immuno-oncology [2] Contact Information - Investor and media inquiries can be directed to PJ Kelleher at LifeSci Advisors, with contact details provided [3]

Core Insights - Wei Fu, Chairman of the Board of I-Mab, intends to purchase up to $2,000,000 of the Company's American Depository Shares (ADSs) in open market transactions [1] - The Company has successfully executed its corporate strategy for 2024, with a focus on increasing shareholder value through portfolio prioritization [2] - I-Mab's lead clinical program is givastomig, a Claudin 18.2 x 4-1BB bispecific antibody, with data expected in early second half of 2025 [2] - The current cash runway for I-Mab extends into 2027 [2] Company Overview - I-Mab is a U.S.-based global biotech company focused on developing precision immuno-oncology agents for cancer treatment [3] - The Company has established operations in Rockville, Maryland, and Short Hills, New Jersey [3]

Core Viewpoint - I-Mab is focusing on advancing its lead program, givastomig, a bispecific antibody targeting CLDN18.2 for the treatment of first-line metastatic gastric cancers and potentially other solid tumors, as part of its strategic outlook for 2025 [1][2][3] Portfolio Prioritization - Givastomig (TJ033721 / ABL111) is designed to target CLDN18.2-positive tumor cells and conditionally activate T cells through the 4-1BB signaling pathway [3] - The drug has shown strong tumor-binding properties and anti-tumor activity in Phase 1 trials, with a favorable safety profile and minimal toxicities compared to other 4-1BB agents [3][6] - A Phase 1b dose escalation study of givastomig in combination with nivolumab plus chemotherapy has been fully enrolled, with data expected in early second half of 2025 [5][6] Financial Outlook - The company reported a cash balance of $184.4 million as of September 30, 2024, which is expected to support operations into 2027 [5][8] - The current cash position is anticipated to fund the givastomig Phase 1b study through dose expansion data readouts and further development initiatives [8] Clinical Development - The company has completed enrollment of a dose escalation study of givastomig, with an overall response rate of 16.3% observed in early data [6] - The ongoing studies are evaluating patients with tumors expressing CLDN18.2, regardless of PD-L1 expression, with data from a 40-patient dose expansion study expected in early 2026 [6] Strategic Focus - The company has paused the development of uliledlimab to concentrate resources on advancing givastomig, while continuing to monitor data from ongoing studies [11]

Group 1 - I-Mab will present at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024 [1] - The presentation will be led by Sean Fu, CEO, and Phillip Dennis, CMO [2] - One-on-one and small group meetings with management will take place on December 3-4, 2024 [2] Group 2 - I-Mab is a U.S.-based global biotech company focused on developing differentiated immunotherapies for cancer treatment [3] - The company has established operations in Rockville, Maryland, and Short Hills, New Jersey [3]

Core Insights - I-Mab is advancing its pipeline with promising data for its immunotherapy candidates, particularly uliledlimab and givastomig, as presented at major medical conferences [1][2][4][6] - The company appointed Dr. Sean Fu as the permanent CEO effective November 1, 2024, indicating a stable leadership transition [1][10] - I-Mab has a strong cash position of $184.4 million, expected to fund operations into 2027 [1][11] Pipeline Overview - Uliledlimab (CD73 antibody) is set to enter a randomized Phase 2 study in first-line metastatic non-small cell lung cancer (mNSCLC) in 1H 2025 [1][5] - Givastomig (Claudin 18.2 x 4-1BB bispecific antibody) is undergoing a Phase 1b study in combination with nivolumab plus chemotherapy for first-line metastatic gastric cancer, with topline data expected in 2H 2025 [5][8] - Ragistomig (PD-L1 x 4-1BB bispecific antibody) is in ongoing Phase 1 studies for advanced solid tumors [8] Clinical Data Highlights - Phase 1 data for uliledlimab showed full target engagement and a positive correlation between overall response rate (ORR) and drug exposure in mNSCLC patients [4] - Givastomig demonstrated an ORR of 16.3% in gastric cancer patients, with a favorable safety profile and no dose-limiting toxicities [6][7] - The optimal monotherapy dose range for givastomig was defined as 8-12 mg/kg, with ongoing studies supporting this dosage [6][7] Financial Performance - Research and development expenses for Q3 2024 were $4.5 million, a decrease from $5.1 million in Q3 2023, attributed to streamlined clinical activities [13] - Administrative expenses increased to $7.9 million in Q3 2024 from $5.9 million in Q3 2023, primarily due to legal costs [14] - The net loss from continuing operations was $(20.5) million for Q3 2024, compared to $(8.2) million in Q3 2023 [16] Strategic Developments - A collaboration agreement with Sanofi for uliledlimab in Greater China includes initial and milestone payments totaling approximately €32 million, with potential for up to €213 million in success-based milestones [10] - The company settled approximately $15 million in repurchase obligations related to its China operations, resulting in a 15% ownership in TJ Bio post-settlement [10]

Core Viewpoint - I-Mab has appointed Sean (Xi-Yong) Fu, PhD, MBA as the permanent CEO effective November 1, 2024, after serving as Interim CEO since July 15, 2024, which is seen as a significant step towards advancing the company's mission in cancer immunotherapy [1][2]. Company Overview - I-Mab is a U.S.-based global biotech company focused on developing highly differentiated immunotherapies for cancer treatment, with operations in Rockville, Maryland, and Short Hills, New Jersey [3]. Leadership and Experience - Dr. Fu has over 20 years of experience in the life sciences industry, including roles as Operating Partner at ABio-X and co-founder and CEO of RVAC Medicines, with a strong background in clinical-stage asset development and organizational leadership [2]. - His previous experience includes a 15-year tenure at Merck & Co., where he managed finances for late-stage clinical portfolios and led the integration of global R&D following a $42 billion merger [2]. Strategic Vision - Dr. Fu expressed excitement about leading I-Mab and emphasized the team's dedication to advancing their differentiated portfolio of immunotherapies, aiming to reach important upcoming milestones [2].

Company Overview - I-Mab is a US-based global biotech company focused on developing highly differentiated immunotherapies for cancer treatment [3]. Financial Results Announcement - I-Mab plans to release its financial results for the third quarter ended September 30, 2024, on November 14, 2024, before the market opens [1]. - The company will not host a conference call to discuss the third quarter financial results [2]. Future Communications - I-Mab intends to hold an investor update call in conjunction with its 2024 full-year financial results to discuss its clinical pipeline, corporate strategy, and objectives [2].

ROCKVILLE, Md., Oct. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meetings with investors at the Truist Securities BioPharma Symposium on November 7, 2024. Event Details Meeting Date Thursday, November 7, 2024 Meetings One-on-one and small group meetings: November 7, 2024 Sean Fu, PhD ...

I-Mab Sponsored ADR (IMAB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing earning ...

Expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, shows promising single-agent activity in heavily pre-treated patients with gastric cancers expressing Claudin 18.2 at low and high levelsThe recommended Phase 2 dose for givastomig was determined to be 8-12 mg/kg; givastomig was well tolerated up to the highest study dosesA Phase 1b study, evaluating givastomig in combination with standard-of-care treatment (nivolumab + chemotherapy (FOLFOX)) in fro ...